MedTrace Logo

Reinforcing Effects of Marijuana and Opioids

NCT05485012 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-04-15

Study results available
· View outcomes & findings →

Summary

The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.

Conditions

  • Marijuana Use
  • Opioid Use

Interventions

DRUG

Marijuana

Double-blind administration of marijuana

DRUG

Opioid

Double-blind administration of an opioid agonist

Sponsors & Collaborators

  • Shanna Babalonis, PhD

    lead OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

Principal Investigators

  • Shanna Babalonis, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-03
Primary Completion
2025-03-27
Completion
2025-03-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485012 on ClinicalTrials.gov